Sangamo Therapeutics (SGMO) Tops Q3 Earnings and Revenue Estimates
Portfolio Pulse from
Sangamo Therapeutics (SGMO) reported Q3 earnings of $0.04 per share, surpassing the Zacks Consensus Estimate of a loss of $0.03 per share. This marks a significant improvement from a loss of $0.34 per share a year ago.
November 12, 2024 | 11:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sangamo Therapeutics reported better-than-expected Q3 earnings, with a profit of $0.04 per share against an expected loss of $0.03. This is a significant improvement from the previous year's loss of $0.34 per share.
The better-than-expected earnings report is likely to positively impact SGMO's stock price in the short term. The significant improvement from the previous year's loss indicates strong financial performance, which is typically viewed favorably by investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100